Naturally, there is some correlation between salary and job satisfaction (Figure 5). "Very satisfied" are the nearly 48% of
respondents earning between $75,000 and $100,000, the 41% earning over $100,000 and the 38% earning between 50,001 and $75,000.
Figure 5. Salary and job satisfaction are linked.
Surprisingly, 16% of those earning over $100,000 are "somewhat dissatisfied," as are the 27% earning between $25,000 and $75,000.
As for European respondents, 67% earning 75,001–120,000 ($97,000–156,000) were very satisfied, as were 42% earning 45,001–55,000
($58,000–71,000); and 33% earning 55,001–65,000 ($71,000–97,000).
However, 40% of those earning 65,001–75,000 ($71,000–97,000) are somewhat dissatisfied. And an equal number (30%) of those
making less than 10,000 ($13,000), and 35,001–45,000 ($45,000–58,000), respectively, are also somewhat dissatisfied.
SECURITY IS EVERYTHING
Because of the rapid growth of the biopharmaceutial industry, there has been a great deal of change. Within the past two years,
nearly half (47%) of respondents report that they have been through a merger, acquisition, or corporate restructuring. This
did not affect 43% of respondents; it led to a change in job responsibilities for 37%, involuntary departure for 12%, and
voluntary leaving for 7%. Despite all this, 68% of all respondents feel secure (Figure 6).
Figure 6. Sense of security
When asked to rate the likelihood of leaving their jobs within the next 12 months, 27% of respondents are likely to leave
theirs, and 45% are not likely to leave. A new job with a better salary, more satisfying work, or an involuntary departure
are the top reasons for leaving jobs (Figure 7).
Figure 7. Reasons for possibly leaving current position
On the whole, survey respondents are satisfied with their work and their salaries. Some 24% even reported working between
six and 10 vacation days in 2005, such as responding to emails and phone calls. Either they love their jobs so much they want
to work during vacation, or they love their jobs in spite of having to do so.
Marilyn Kochman is the managing editor of BioPharm International, 732.346.3061, MKochman@advanstar.com